CY1117478T1 - Πεπτιδιο ικανο να παρατεινει το χρονο ημιζωης πεπτιδιου ενδιαφεροντος στο πλασμα - Google Patents
Πεπτιδιο ικανο να παρατεινει το χρονο ημιζωης πεπτιδιου ενδιαφεροντος στο πλασμαInfo
- Publication number
- CY1117478T1 CY1117478T1 CY20161100242T CY161100242T CY1117478T1 CY 1117478 T1 CY1117478 T1 CY 1117478T1 CY 20161100242 T CY20161100242 T CY 20161100242T CY 161100242 T CY161100242 T CY 161100242T CY 1117478 T1 CY1117478 T1 CY 1117478T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peptide
- represented
- integer
- plasma
- extend
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/63—Motilins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Πεπτίδιο του ακόλουθου (I) ή (II). (I) πεπτίδιο παριστώμενο από τον τύπο Β, Α-Β, B-C ή A-B-C στους οποίους οι Α, Β και C παρίσταται έκαστη από τα ακόλουθα (1), (2) και (3) και, όταν είναι ενωμένο σε άλλο πεπτίδιο-αντικείμενο, είναι ικανό να παρατείνει το χρόνο ημιζωής στο πλάσμα σε σύγκριση με το πεπτίδιο-αντικείμενο, με τη φυσιολογική δραστικότητα του πεπτιδίου-αντικειμένου να διατηρείται. (II) πεπτίδιο που περιλαμβάνει ανεστραμμένη αλληλουχία του πεπτιδίου του (I)· αλληλουχία η οποία παριστάται από Α-Β στο (I) και η Α ή Β είναι ανεστραμμένη· αλληλουχία η οποία παριστάται από B-C στο (I) και η Β ή C είναι ανεστραμμένη· ή αλληλουχία η οποία παριστάται από A-B-C στο (I) και οι Α, Β, C, Α και Β, και Β και C ή Α και C είναι διατηρημένη. (1) Η Α είναι πεπτίδιο που περιλαμβάνει 1 έως 14 οιωνδήποτε αμινοξέων (2) Η Β είναι πεπτίδιο που παρίσταται από τον τύπο 1: (Wk-X1-Y-Zm-Wn)-(Wo-Xp-Y-Zq-Wr)s (Στον τύπο 1, η W είναι βασικό αμινοξύ· οι Χ και Ζ είναι οιαδήποτε αμινοξέα· η Υ είναι όξινο αμινοξύ· k είναι 1 ή 2· 1 είναι ακέραιος 4 ≥ 1 ≥ 0· m είναι ακέραιος 2 ≥ m ≥ 0· 4 ≥ 1 + m ≥ 0· n είναι 1 ή 2· ο είναι 1 ή 2· p είναι ακέραιος 4 ≥ p ≥ 0· q είναι ακέραιος 2 ≥ q ≥ 0· 4 ≥ p+q ≥ 0· r είναι 1 ή 2· και s είναι 0 ή 1). (3) Η C είναι πεπτίδιο που περιλαμβάνει 2 έως 14 οιωνδήποτε αμινοξέων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008136106 | 2008-05-23 | ||
EP09750669.5A EP2277890B1 (en) | 2008-05-23 | 2009-05-22 | Peptide capable of extending half-life of peptide of interest in plasma |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117478T1 true CY1117478T1 (el) | 2017-04-26 |
Family
ID=41340233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100242T CY1117478T1 (el) | 2008-05-23 | 2016-03-22 | Πεπτιδιο ικανο να παρατεινει το χρονο ημιζωης πεπτιδιου ενδιαφεροντος στο πλασμα |
Country Status (16)
Country | Link |
---|---|
US (1) | US8551937B2 (el) |
EP (1) | EP2277890B1 (el) |
JP (1) | JP5524049B2 (el) |
KR (2) | KR20130018965A (el) |
CN (1) | CN101809029B (el) |
BR (1) | BRPI0904622A2 (el) |
CA (1) | CA2698582C (el) |
CY (1) | CY1117478T1 (el) |
DK (1) | DK2277890T3 (el) |
ES (1) | ES2566830T3 (el) |
HR (1) | HRP20160303T1 (el) |
HU (1) | HUE028539T2 (el) |
PL (1) | PL2277890T3 (el) |
PT (1) | PT2277890E (el) |
SI (1) | SI2277890T1 (el) |
WO (1) | WO2009142307A1 (el) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005235635B2 (en) | 2004-04-21 | 2010-11-18 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
CA2758581C (en) | 2009-05-20 | 2022-06-14 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
AU2011350066A1 (en) | 2010-12-27 | 2013-07-11 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
EP2481751A1 (en) * | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Human lactoferrin derived peptides |
US20140072557A1 (en) | 2011-02-28 | 2014-03-13 | National Cerebral And Cardiovascular Center | Medicinal agent for suppressing malignant tumor metastasis |
KR20140054084A (ko) | 2011-08-19 | 2014-05-08 | 도쿠리츠교세이호진 고쿠리츠쥰칸키뵤 겐큐센터 | 나트륨 이뇨 펩티드 수용체 gc-a 아고니스트 및 gc-b 아고니스트를 조합하여 이루어지는 악성 종양의 악화 방지용 의약 |
JPWO2013099376A1 (ja) * | 2011-12-26 | 2015-04-30 | 国立大学法人福井大学 | 体外受精における成熟卵子マーカー及びその使用 |
TWI578995B (zh) * | 2012-04-25 | 2017-04-21 | 第一三共股份有限公司 | 利尿鈉肽受體npr-b促效劑之用途 |
AU2013263349B2 (en) | 2012-05-17 | 2016-09-08 | Extend Biosciences, Inc | Carriers for improved drug delivery |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
TW201442721A (zh) | 2013-01-23 | 2014-11-16 | Daiichi Sankyo Co Ltd | 糖鏈修飾心房利尿鈉肽 |
JPWO2015129812A1 (ja) * | 2014-02-27 | 2017-03-30 | 第一三共株式会社 | ステロイド剤投与で誘発される成長障害に対する医薬 |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
CA2964463C (en) | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
US11352612B2 (en) | 2015-08-17 | 2022-06-07 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
EP3355904A4 (en) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA |
US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
PL3400019T3 (pl) * | 2016-01-08 | 2023-01-23 | Ascendis Pharma Growth Disorders A/S | Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy |
WO2017155569A1 (en) | 2016-03-08 | 2017-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
JP2019513711A (ja) | 2016-04-01 | 2019-05-30 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
EP3452021B1 (en) * | 2016-05-06 | 2021-12-29 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
WO2017214130A1 (en) | 2016-06-06 | 2017-12-14 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
EP3574913A4 (en) | 2017-01-24 | 2020-07-22 | Daiichi Sankyo Company, Limited | SMALL SIZE THERAPEUTIC AGENT |
EP3601314A4 (en) * | 2017-03-22 | 2021-01-13 | Pharmain Corporation | NPRA AGONISTS, COMPOSITIONS AND CORRESPONDING USES |
AU2018243320A1 (en) | 2017-03-31 | 2019-10-10 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
JP7378839B2 (ja) * | 2018-12-26 | 2023-11-14 | スキンメドカンパニーリミテッド | アセチルコリン受容体阻害ペプチド及びその用途 |
MX2021015160A (es) | 2019-06-12 | 2022-03-17 | Novartis Ag | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso. |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3026354B2 (ja) * | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトcnp遺伝子及び前駆体蛋白 |
US20060263382A1 (en) * | 1998-06-20 | 2006-11-23 | Richard Hotchkiss | Membrane-permeant peptide complexes for treatment of sepsis |
US7385026B1 (en) | 1999-07-23 | 2008-06-10 | Kenji Kangawa | Modified ghrelin polypeptides |
EP1427750B1 (en) | 2001-08-30 | 2010-12-08 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
ES2355488T3 (es) * | 2001-08-30 | 2011-03-28 | Biorexis Technology, Inc. | Proteína de fusión de tranferrina modificadas. |
US20090181888A1 (en) * | 2005-11-21 | 2009-07-16 | Noboru Murakami | Skin Repair Accelerating Therapeutic Agent Containing Ghrelin and Derivatives Thereof or Substance Acting On GHS-R1a as Active Ingredient |
CA2630011A1 (en) * | 2005-11-21 | 2007-05-24 | University Of Miyazaki | Skin repair accelerating therapeutic agent containing desacyl ghrelin and derivatives thereof as active ingredient |
JPWO2008018597A1 (ja) * | 2006-08-11 | 2010-01-07 | 国立大学法人 宮崎大学 | デスアシルグレリン及びその誘導体を有効成分とする脊髄神経修復促進治療剤 |
RU2009108643A (ru) * | 2006-08-11 | 2010-09-20 | Юниверсити Оф Миязаки (Jp) | Лекарственные средства, усиливающие репарацию спинномозговых нервов, содержащие в качестве активного ингредиента грелин или его производные или вещества, которые действуют на ghs-r1а |
US20100034194A1 (en) * | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
-
2009
- 2009-05-22 CN CN200980100291.9A patent/CN101809029B/zh not_active Expired - Fee Related
- 2009-05-22 PL PL09750669T patent/PL2277890T3/pl unknown
- 2009-05-22 JP JP2010513074A patent/JP5524049B2/ja not_active Expired - Fee Related
- 2009-05-22 ES ES09750669.5T patent/ES2566830T3/es active Active
- 2009-05-22 KR KR1020127034358A patent/KR20130018965A/ko not_active Application Discontinuation
- 2009-05-22 WO PCT/JP2009/059464 patent/WO2009142307A1/ja active Application Filing
- 2009-05-22 KR KR1020107004795A patent/KR101350251B1/ko active IP Right Grant
- 2009-05-22 US US12/675,961 patent/US8551937B2/en active Active
- 2009-05-22 HU HUE09750669A patent/HUE028539T2/en unknown
- 2009-05-22 SI SI200931387T patent/SI2277890T1/sl unknown
- 2009-05-22 CA CA2698582A patent/CA2698582C/en not_active Expired - Fee Related
- 2009-05-22 PT PT97506695T patent/PT2277890E/pt unknown
- 2009-05-22 EP EP09750669.5A patent/EP2277890B1/en active Active
- 2009-05-22 DK DK09750669.5T patent/DK2277890T3/en active
- 2009-05-22 BR BRPI0904622A patent/BRPI0904622A2/pt not_active Application Discontinuation
-
2016
- 2016-03-22 CY CY20161100242T patent/CY1117478T1/el unknown
- 2016-03-23 HR HRP20160303TT patent/HRP20160303T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2698582A1 (en) | 2009-11-26 |
KR101350251B1 (ko) | 2014-01-14 |
JP5524049B2 (ja) | 2014-06-18 |
EP2277890A4 (en) | 2011-08-24 |
CN101809029B (zh) | 2016-06-15 |
ES2566830T3 (es) | 2016-04-15 |
EP2277890A1 (en) | 2011-01-26 |
JPWO2009142307A1 (ja) | 2011-09-29 |
PT2277890E (pt) | 2016-03-31 |
BRPI0904622A2 (pt) | 2016-06-21 |
CN101809029A (zh) | 2010-08-18 |
SI2277890T1 (sl) | 2016-04-29 |
KR20130018965A (ko) | 2013-02-25 |
HRP20160303T1 (hr) | 2016-04-22 |
KR20100038236A (ko) | 2010-04-13 |
HUE028539T2 (en) | 2016-12-28 |
US20100305031A1 (en) | 2010-12-02 |
WO2009142307A1 (ja) | 2009-11-26 |
EP2277890B1 (en) | 2016-01-06 |
PL2277890T3 (pl) | 2016-06-30 |
US8551937B2 (en) | 2013-10-08 |
DK2277890T3 (en) | 2016-02-08 |
CA2698582C (en) | 2016-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117478T1 (el) | Πεπτιδιο ικανο να παρατεινει το χρονο ημιζωης πεπτιδιου ενδιαφεροντος στο πλασμα | |
CY1121658T1 (el) | Πεπτιδια και χρηση αυτων | |
ES2616658T3 (es) | Péptidos que mimetizan el factor de crecimiento y sus usos | |
ES2691539T3 (es) | Luciferasas de Oplophorus sintéticas con mayor emisión de luz | |
CY1123387T1 (el) | Συνδυασμος δυο αντιιικων για τη θεραπεια της ηπατιτιδας c | |
CY1124146T1 (el) | Συστηματα εκφρασης | |
CY1120407T1 (el) | Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως | |
CY1120426T1 (el) | Πολυπεπτιδιο ace2 | |
CY1120417T1 (el) | Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων | |
BR112013023911A2 (pt) | amidas de ácido n-(1,3,4-oxadiazol-2-il)-arilcarboxílico e o uso das mesmas como herbicidas | |
TR201907397T4 (tr) | Il-15 ve ıl-15 alfa suşi alanı bazlı immünositokinler. | |
CY1117934T1 (el) | Αντιβακτηριακες φαρμακευτικες συνθεσεις | |
DE602005008996D1 (de) | Radiofluorierte peptide | |
CY1112182T1 (el) | Μεθοδος για την αμιδιωση πολυπεπτιδιων με καρβοξυτελικα βασικα αμινοξεα με τη χρηση ειδικων ενδοπρωτεασων | |
BR112014000466A2 (pt) | polipeptídeos quiméricos e híbridos fator viii, métodos de uso dos mesmos | |
CY1111225T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c | |
EA201491155A1 (ru) | Новые мутантные про-нрф и их применение для получения бета-нрф | |
AR076977A1 (es) | Proteinas precursoras repetitivas autoensambladas | |
CY1113752T1 (el) | Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv | |
CY1120424T1 (el) | Πεπτιδια λαμβανομενα απο ανθρωπινη bplp πρωτεϊνη, πολυνουκλεοτιδια που κωδικοποιουν τα εν λογω πεπτιδια και αντισωματα κατευθυνομενα εναντι των εν λογω πεπτιδιων | |
CY1113115T1 (el) | Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες | |
AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
CY1112614T1 (el) | Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης | |
ES2570458T3 (es) | Peptidomiméticos fijados sobre una matriz con actividad moduladora de CXCR7 | |
PL415888A1 (pl) | Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie |